Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPIRE-AF
2023-509142-35-00Phase 4Authorised
- Sponsor
- Hamilton Health Sciences
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 4, randomised trial of rivaroxaban, dabigatran, edoxaban and apixaban in Atrial fibrillation (AFib) (2 arms), sponsored by Hamilton Health Sciences. Primary endpoints: Individual components of the co-primary outcomes, All stroke and 1 more. Planned start Jan 2024; status: authorised.
02
Drugs
rivaroxabandabigatranedoxabanapixaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2023-509142-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509142-35-00.